DVT prophylaxis - new oral anticoagulant - elective hip replacement clinical trials results meta-analysis

<h1> <a href="index.html"> <strong>DVT prophylaxis</strong> - new oral anticoagulant </a> - elective hip replacement trial results systematic overview and meta-analysis </h1> <h2>Main characteristics of the included studies</h2> <table> <tr> <th>Trial</th> <th>Treatments</th> <th>Patients</th> <th>Methods</th> </tr> <tr> <td> <a href="TRC_t6729.html"> RE-NOVATE (220mg), 2007 </a> <br> NCT00168818 </td> <td> dabigatran etexilate 220 mg q.d. for 28-35 days<br>  <i>versus</i> <br> Enoxaparin 40 mg q.d. </td> <td> Total hip replacement </td> <td> follow-up 28-35 days, median 33d<br> n=1157/1162<br> Parallel groups<br> double blind <br> Europe, Australia, South Africa </td> </tr> <tr> <td> <a href="index.html"> RE-NOVATE (150mg), 2007 </a> <br> NCT00168818 </td> <td> dabigatran etexilate 150 mg q.d. 28-35 days <br>  <i>versus</i> <br> Enoxaparin 40 mg q.d. </td> <td> Total hip replacement </td> <td> follow-up 28-35 days, median 33d<br> n=1174/1162<br> <br> double blind <br> Europe, Australia, South Africa </td> </tr> <tr> <td> <a href="index.html"> BISTRO II (225mg bid), 2005 </a> <br> </td> <td> dabigatran etexilate 225 mg twice daily for 6�10 days<br>  <i>versus</i> <br> subcutaneous enoxaparin 40 mg once daily </td> <td> patients undergoing total hip or knee replacement </td> <td> follow-up <br> n=393/392<br> Parallel groups<br> double blind <br> Europe and South Africa (2 centres) </td> </tr> <tr> <td> <a href="index.html"> ODIXa-HIP 10mg, 2006 </a> <br> </td> <td> rivaroxaban 10mg daily for 5�9 days<br>  <i>versus</i> <br> once-daily subcutaneous enoxaparin dose of 40 mg for 5�9 days </td> <td> patients undergoing elective total hip replacement </td> <td> follow-up 5-9 days<br> n=142/157<br> Parallel groups<br> double blind <br> Europe, Israel </td> </tr> <tr> <td> <a href="index.html"> RECORD 1, 2008 </a> <br> NCT00329628 </td> <td> rivaroxaban 10mg once daily for 35 days<br>  <i>versus</i> <br> enoxaparin 40mg subcutaneous once daily </td> <td> patients undergoing total hip arthroplasty </td> <td> follow-up 36 days (range 30-42)<br> n=2209/2224<br> Parallel groups<br> double blind <br> 27 countries worldwide </td> </tr> <tr> <td> <a href="index.html"> RECORD 2, 2008 </a> <br> NCT00332020 </td> <td> extended thromboprophylaxis with rivaroxaban 10mg once daily for 31-39 days<br>  <i>versus</i> <br> short-term thromboprophylaxis with enoxaparin 40mg subcutaneous once daily for 10-14 days </td> <td> patients undergoing elective total hip replacement </td> <td> follow-up 30-42 days<br> n=1252/1257<br> Parallel groups<br> double blind <br> 21 countries worldwide </td> </tr> <tr> <td> <a href="TRC_t11113.html"> RE-NOVATE 2, 2010 </a> <br> NCT00657150 </td> <td> dabigatran 220mg once daily for 28-35 Days<br>  <i>versus</i> <br> enoxaparin 40mg subcutaneous </td> <td> patients undergoing total hip-replacement surgery </td> <td> follow-up 28-35 days (mean 32d)<br> n=1010/1003<br> Parallel groups<br> double-blind <br> </td> </tr> <tr> <td> <a href="TRC_t10332.html"> CV185-035, </a> <br> NCT00423319 </td> <td> apixaban 2.5mg twice daily 5 weeks<br>  <i>versus</i> <br> enoxaparin 40mg once daily 5 weeks </td> <td> patients undergoing elective total hip replacement surger </td> <td> follow-up 35 days<br> n=5406/0<br> Parallel groups<br> double blind <br> </td> </tr> </table> <h2>References</h2> <p> <b>RE-NOVATE (220mg), 2007 : </b> Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, B�ller HRDabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. <i>Lancet 2007;370:949-56</i> [PMID 17869635] </p> <p> <b>RE-NOVATE (150mg), 2007 : </b> Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, B�ller HRDabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. <i>Lancet 2007;370:949-56</i> [PMID 17869635] </p> <p> <b>BISTRO II (225mg bid), 2005 : </b> Eriksson BI, Dahl OE, B�ller HR, Hettiarachchi R, Rosencher N, Bravo ML, Ahnfelt L, Piovella F, Stangier J, K�lebo P, Reilly PA new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. <i>J Thromb Haemost 2005 Jan;3:103-11</i> [PMID 15634273] </p> <p> <b>ODIXa-HIP 10mg, 2006 : </b> Eriksson BI, Borris L, Dahl OE, Haas S, Huisman MV, Kakkar AK, Misselwitz F, K�lebo POral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. <i>J Thromb Haemost 2006 Jan;4:121-8</i> [PMID 16409461] </p> <p> <b>ODIXa-HIP 10mg, 2006 : </b> Eriksson BI, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, Muehlhofer E, Dierig C, Misselwitz F, K�lebo PA once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. <i>Circulation 2006 Nov 28;114:2374-81</i> [PMID 17116766] </p> <p> <b>RECORD 1, 2008 : </b> Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts WRivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty <i>N Engl J Med 2008;358:2765-75</i> [PMID 18579811] 10.1056/NEJMoa0800374 </p> <p> <b>RECORD 2, 2008 : </b> Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas SExtended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. <i>Lancet 2008 Jun 24;:</i> [PMID 18582928] </p>